We are live on
!
Find out more
ICM
Invenomic Capital Management Portfolio holdings
AUM
$2.18B
1-Year Est. Return
0.03%
This Fund
S&P 500
This Quarter
Est. Return
+4.65%
1 Year Est. Return
+0.03%
3 Year Est. Return
-6.37%
5 Year Est. Return
-25.27%
10 Year Est. Return
–
AUM
$418M
AUM Growth
-$30.8M
(-6.9%)
Cap. Flow
-$37.5M
Cap. Flow
% of AUM
-8.97%
Top 10 Holdings %
Top 10 Hldgs %
54.35%
Holding
163
New
44
Increased
31
Reduced
48
Closed
39
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SRGA
Surgalign Holdings, Inc. Common Stock
SRGA
|
+$3.75M |
| 2 |
DISCK
Discovery, Inc. Series C Common Stock
DISCK
|
+$3.59M |
| 3 |
Teck Resources
TECK
|
+$3.58M |
| 4 |
Popular Inc
BPOP
|
+$3.3M |
| 5 |
GTS
Triple-S Management Corporation
GTS
|
+$3.17M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Molson Coors Class B
TAP
|
+$3.57M |
| 2 |
UGI
UGI
|
+$3.26M |
| 3 |
Universal Health Services
UHS
|
+$3.1M |
| 4 |
Wells Fargo
WFC
|
+$3.08M |
| 5 |
Concrete Pumping Holdings
BBCP
|
+$2.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 9.06% |
| 2 | Industrials | 7.6% |
| 3 | Materials | 7.59% |
| 4 | Consumer Discretionary | 5.8% |
| 5 | Healthcare | 5.63% |
Similar funds
SIG
CAG
SQA
SCP
OWP
ORCP
ET
MMLI
Invenomic Capital Management's Q2 2021 Portfolio in Review
As of Q2 2021, Invenomic Capital Management held 163 positions worth $418M, down 6.9% from $448M the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Invenomic Capital Management withdrew a net $37.5M in Q2 2021, closing 39 positions and reducing 48 holdings. Its most notable exit was UGI, an estimated $3.26M position sold in full.
By sector, the portfolio is most concentrated in Financials at 9.1% of assets, up from 6.9% a quarter earlier, followed by Industrials and Materials.
Against the trend, Invenomic Capital Management opened a new position in Popular Inc worth $3.23M.
- Invenomic Capital Management's largest Q2 2021 buy was Popular Inc: 43,078 shares worth $3.23M.
- Invenomic Capital Management added most to Surgalign Holdings, Inc. Common Stock in Q2 2021, an estimated $3.75M increase.
- Invenomic Capital Management's biggest Q2 2021 reduction was Molson Coors Class B, cutting an estimated $3.57M.
- Invenomic Capital Management fully exited UGI in Q2 2021, selling an estimated $3.26M.
- Invenomic Capital Management's ten largest holdings make up 54% of its $418M portfolio in Q2 2021.
- Invenomic Capital Management opened 44 new positions and closed 39 in Q2 2021.
- Invenomic Capital Management's portfolio value fell 6.9% quarter-over-quarter to $418M.
Based on Invenomic Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.